The stock will trade on pipeline catalysts (DLB partnership, nfvPPA data in Oct/Nov 2026) rather than the modest EPS miss. Monitor for a strategic partnership announcement for Phase 3 DLB — that is the primary value inflection point. The $20.5M June financing removes near-term dilution risk but the company remains pre-revenue with no approved products.
Price Chart
Executive Summary
CervoMed reported Q2 2026 results with a net loss of $6.6M ($-0.64 EPS, a 3.2% miss vs consensus $-0.62), no grant revenue, and $24.9M cash extending runway through Q3 2027. The filing is dominated by pipeline updates — neflamapimod data at AAIC 2026 supporting a Phase 3 DLB trial, an Innovation Passport designation from the UK, and completed equity financings raising ~$20.5M — but the core financials show a widening loss and zero revenue, making this a neutral-to-slightly-negative event for a pre-revenue biotech.
Key Financial Metrics
Key Facts
- Net loss of $6.6M for Q2 2026 vs $6.3M in Q2 2025, a $0.3M increase.
- EPS of $-0.64 missed consensus estimate of $-0.62 by 3.2%.
- No grant revenue recognized in Q2 2026 vs $1.8M in Q2 2025 due to completion of the RewinD-LB trial.
- Cash, cash equivalents and marketable securities of $24.9M as of June 30, 2026, extending runway through Q3 2027.
- Completed two equity financings in June 2026 for aggregate gross proceeds of ~$20.5M.
- Neflamapimod awarded Innovation Passport Designation under the UK's ILAP for DLB.
- New AAIC 2026 data supports 50 mg TID dose for planned Phase 3 DLB trial and reinforces treatment effect in pure DLB.
- Enrollment completed in Phase 2a nfvPPA trial (25 participants); initial biomarker data expected at ISFTD in October 2026.
- Ended enrollment in Phase 2a RESTORE stroke trial; topline data expected H2 2026.
- Expects to dose first patient in EXPERTS-ALS trial by end of 2026.
Financial Impact
Net loss increased $0.3M YoY to $6.6M; cash burn rate ~$2.5M/month based on $24.9M cash providing ~14 months runway
Risk Factors
- No grant revenue going forward; fully dependent on equity/debt financing or partnership for operations.
- Phase 3 DLB trial requires a strategic partner — no guarantee of finding one on acceptable terms or timeline.
- RewinD-LB Phase 2b primary endpoint was not met; efficacy relies on subgroup and exploratory analyses.
- Cash runway only through Q3 2027; additional financing likely needed before Phase 3 data readout.
- Competing DLB therapies from larger players could limit commercial opportunity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-026771 |
| Document: crvo20260810_8k.htm | 0001437749-26-026771 |
| Document: 0001437749-26-026771-index-headers.html | 0001437749-26-026771 |
| Document: 0001437749-26-026771-index.html | 0001437749-26-026771 |
| Document: 0001437749-26-026771.txt | 0001437749-26-026771 |
| 8-K Data (Synthetic) | 0001437749-26-026771 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $2.25 $2.24 | ▼ −0.44% | ▲ +0.66% | $2.24 (−0.44%) |
Oct 13, 2026 13d ago | 8-K | $2.27 $2.29 | ▲ +0.88% | ▲ +1.96% | $2.24 (−1.32%) |
Oct 9, 2026 17d ago | 8-K | $2.51 $2.27 | ▼ −9.56% | ▼ −9.55% | $2.24 (−10.76%) |
Sep 10, 2026 6w ago | Press Release | $2.48 $2.57 | ▲ +3.63% | ▲ +2.78% | $2.24 (−9.68%) |
Aug 10, 2026 11w ago | 8-K | $3.09 $3.07 | ▼ −0.65% | ▼ −0.90% | $2.24 (−27.51%) |
Aug 4, 2026 11w ago | 8-K | $2.80 $2.81 | ▲ +0.36% | ▲ +0.56% | $2.24 (−20.00%) |
Aug 4, 2026 11w ago | Press Release | $2.80 $2.81 | ▲ +0.36% | ▲ +0.56% | $2.24 (−20.00%) |
Jul 13, 2026 15w ago | EFFECT | $3.31 $3.08 | ▲ +6.95% | ▲ +7.30% | $2.24 (+32.33%) |
Jul 6, 2026 16w ago | S-3 | $3.42 $3.41 | ▲ +0.29% | ▼ −0.02% | $2.24 (+34.50%) |
Jun 22, 2026 18w ago | 8-K | $3.72 $3.26 | ▲ +12.37% | ▲ +12.32% | $2.24 (+39.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers